2023 Solid Tumor Cell Therapy Pine and Cypress Conference will be grandly coming, welcome to scan the code to participate
Immune cell therapy has opened a new era of tumor immunotherapy, and the representative therapy CAR-T has become a "star" in today's hematological tumor treatment. However, in the face of solid tumors with broader clinical needs, cell therapy seems to have a difficult way to go. At present, there are no less than 50 innovative pharmaceutical companies in China engaged in the development of solid tumor cell therapy products and have made clinical progress, including no less than 20 CAR-T therapy developers. In the face of difficulties, we must rise to the occasion.
Immune cell therapy cell therapy has become one of the most competitive emerging industries in the global biotechnology field. On June 30, 2023, KAEDI and JOINN Laboratories (China) Co., ltd will hold the "2023 Solid Tumor Cell Therapy Pine and Cypress Conference"offline, bringing together multiple forces in the industry to conduct in-depth discussions on the whole life cycle of R&D strategy, early development, CMC process, non-clinical evaluation, clinical research and commercialization. In order to promote the development of solid tumor cell therapy in China and benefit the majority of patients. Let's meet together "2023 Solid Tumor Cell Therapy Pine and Cypress Conference", welcome to scan the code to participate, for more wonderful details, please pay attention to the follow-up report.
2023 Solid Tumor Cell Therapy Pine and Cypress Conference
June 30 HUALUXE2023 Solid Tumor Cell Therapy Pine and Cypress Conference
Immune cell therapy has opened a new era of tumor immunotherapy, and the representative therapy CAR-T has become a "star" in today's hematological tumor treatment. However, in the face of solid tumors with broader clinical needs, cell therapy seems to have a difficult way to go. At present, there are no less than 50 innovative pharmaceutical companies in China engaged in the development of solid tumor cell therapy products and have made clinical progress, including no less than 20 CAR-T therapy developers. In the face of difficulties, we must rise to the occasion.
People gathered firewood and kept it high, and people planted trees into forests.
On June 30, 2023, KAEDI and JOINN Laboratories (China) Co., ltd will hold the "2023 Solid Tumor Cell Therapy Pine and Cypress Conference"offline, bringing together multiple forces in the industry to conduct in-depth discussions on the whole life cycle of R&D strategy, early development, CMC process, non-clinical evaluation, clinical research and commercialization. In order to promote the development of solid tumor cell therapy in China and benefit the majority of patients. We sincerely invite you to come to the scene and create a "pine and cypress session"!
Proposed to invite guests
Lixin Wang Deputy Director of the Audit and Inspection Center of Jiangsu Drug Administration
Bin Li Deputy Director of Scientific Research and Research Group Leader of Shanghai Institute of Immunology
Liqun Wang Founder, Chairman and Chief Executive Officer of Neukio
Hongjiu Dai Founder and Chairman of KAEDI
Jing Ma Founder and Chairman of Taichu Biotechnology
Changsong Qi Chief physician of the first ward of Beijing Cancer Hospital
Yang Cao Vice President of Joinn Laboratories (China) Co., Ltd
Rui Yang Vice President of Medicine at Gobo Clinical Research Center
Xiaoyu Zheng CEO of Gobo Medical Clinical Center
Yunyan Li Director of Industry Development at Kaizu Biotechnology
Dichao Hu Assistant Deputy General Manager of Bioton Cell Therapy Process Development
Yan Xia Director of Joinn Laboratories (China) Co., ltd Macromolecular Analysis Technology
Cheng Qian Chongqing Precision Bio CSO
Jinhua Zhang Founder and Chairman of Reindeer Bio
Yu Zhang Deputy General Manager and Chief Scientific Officer of Zhongyuan Concord
Lin Yang Founder of Boshengji Pharmaceutical
Dan Li Co-founder of Sanqing Biotechnology
Fujuan Gao Yinglai Capital Partners
Dan Liu Senior Partner of CDH Investments
Hongyi Zhang Executive General Manager of CICC
Hua Ren Partner of Jingtian & Gongcheng Law Offices
Guangming Zhu Senior partner of Zhonghui Accounting Firm
(Rankings are not divided into front and back)
Agenda of the meeting
08:25-08:30 Leader's speech
Hong Chen Director of Life and Health Industry Development Management Office of Jiangbei New Area, Nanjing Province
08:30-09:00 Key points of on-site verification of CAR-T cell drugs
Lixin Wang Deputy Director of the Audit and Inspection Center of Jiangsu Drug Administration
09:00-09:30 Difficulties and future of cell therapy application in solid tumors from the perspective of PI
Changsong Qi Chief physician of the first ward of Beijing Cancer Hospital
09:30-10:00 Development status and trend of tumor immunotherapy
Bin Li Deputy Director of Scientific Research and Research Group Leader of Shanghai Institute of Immunology
10:00-10:30 Analysis of the commercial feasibility of immune cell therapy drugs for solid tumors
Liqun Wang Founder, Chairman and Chief Executive Officer of Neukio
10:30-11:00 Development history of NKG2DL-targeted CAR-T cell drugs
Hongjiu Dai Founder and Chairman of KAEDI
11:00-11:30 Non-clinical evaluation strategy of CAR-T cells in solid tumors
Jing Ma Founder and Chairman of Taichu Biotechnology
11:30-12:00 Sharing of CAR-T Clinical Study Design Strategy for Solid Tumors
Rui Yang Vice President of Medicine at Gobo Clinical Research Center
12:00-13:30 Lunch
13:30-14:00 From the practical point of view, the key points and ideas of the preclinical evaluation of immune cell therapy products in IND stage were analyzed
Yang Cao Vice President of Joinn Laboratories (China) Co., Ltd
14:00-14:30 Break the barriers of raw materials and help solid tumor cell therapy
Yunyan Li Director of Industry Development at Kaizuo Biotechnology
14:30-15:00 Solid tumor CAR-T CMC development strategy and key points
Dichao Hu Assistant Deputy General Manager of Bioton Cell Therapy Process Development
15:00-15:30 Cell therapy bioanalysis
Yan Xia Director of Joinn Laboratories (China) Co., ltd Macromolecular Analysis Technology
15:30-16:15 Pine and Cypress conversation: A strategy for CAR-T cell drug development in solid tumors
compere锛� Hongjiu Dai Founder and Chairman of KAEDI
Changsong Qi Chief physician of the first ward of Beijing Cancer Hospital
Bin Li Deputy Director of Scientific Research and Research Group Leader of Shanghai Institute of Immunology
Cheng Qian Chongqing Precision Bio CSO
Yang Cao Vice President of Joinn Laboratories (China) Co., Ltd
Dan Li Co-founder of Sanqing Biotechnology
16:15-17:00 Pine and Cypress conversation: CAR-T cell drug commercialization strategy
Compere: Liqun Wang Founder, Chairman and Chief Executive Officer of Neukio
Jinhua Zhang Founder and Chairman of Reindeer Bio
Xiaoyu Zheng CEO of Gobo Medical Clinical Center
Yu Zhang Deputy General Manager and Chief Scientific Officer of Zhongyuan Concord
Lin Yang Founder of Boshengji Pharmaceutical
17:00-17:15 Coffee break
17:15-18:00 Pine and Cypress conversation: IPO strategy of CAR-T cell new drug companies
Compere: Fujuan Gao Yinglai Capital Partners
Dan Liu Senior Partner of CDH Investments
Hongyi Zhang Executive General Manager of CICC
Hua Ren Partner of Jingtian & Gongcheng Law Offices
Guangming Zhu Senior partner of Zhonghui Accounting
18:30-20:30 dinner party
Organization:
Guidance unit:
Organizer:
Co-organizers:
Scan the QR code to register
Pine and cypress, resolute and tall, fighting the cold and snow
Bio-innovative pharmaceutical companies, just like that
About KAEDI
KAEDI is a clinical-stage drug discovery and development company dedicated to developing novel cell drugs with unmet clinical needs in patients with solid tumors using a leading synthetic biology technology platform. Relying on KD-SmCAR™ and KD-ScCAR™, the company's independent CAR library screening platform, and KD-ScCAR™, a dual-targeted CAR development platform. KAEDI has successfully developed a number of new cell drug pipelines for solid tumors, including next-generation autologous and allogeneic CAR-T/CAR-NK pipelines. At present, more than 30 CAR-related patents have been declared and 15 patents have been authorized, among which the core pipeline KD-025, KD-496 and other patents are authorized for the first time in China and the United States. The product development results of KD-025 CAR-T targeting NKG2DL for liver cancer, colorectal cancer and glioma have been published in the international authoritative journal "Journal for ImmunoTherapy of Cancer", "Cancer Immunology Research" and the American annual cancer clinical meeting ASCO. The KD-025 CAR-T IIT clinical trial carried out in a well-known clinical center in China has completed a number of low-dose administrations without obvious toxic side reactions, and the product is safe and effective, and it is the first domestic KEDI is headquartered in Nanjing, China. For more information, please visit the official website of Nanjing Kaidi Medical Technology Co., Ltd.: targeting CAR-T (KD-025) cells targeting NKG2DL solid tumors. The company that IND applied for CDE clinical approval is currently negotiating with a number of partners to start the first clinical phase of KD-025 registration, and at the same time, the company's core product KD-496 has entered the IIT clinical stage as the world's first new dual-targeted CAR-T cell injection. In addition, KAEDI is promoting the layout of the next generation allogeneic universal CAR-T/CAR-NK, and is expected to build KAEDI into a world-renowned solid tumor cell therapy company in the near future.